- Home
- PEGA vs MRNA Comparison
PEGA vs MRNA Comparison
Compare PEGA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- MRNA
- Stock Information
- Founded
- PEGA 1983
- MRNA 2010
- Country
- PEGA United States
- MRNA United States
- Employees
- PEGA N/A
- MRNA N/A
- Industry
- PEGA EDP Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEGA Technology
- MRNA Health Care
- Exchange
- PEGA Nasdaq
- MRNA Nasdaq
- Market Cap
- PEGA 10.2B
- MRNA 9.2B
- IPO Year
- PEGA 1996
- MRNA 2018
- Fundamental
- Price
- PEGA $59.38
- MRNA $24.29
- Analyst Decision
- PEGA Buy
- MRNA Hold
- Analyst Count
- PEGA 12
- MRNA 15
- Target Price
- PEGA $66.08
- MRNA $36.69
- AVG Volume (30 Days)
- PEGA 1.6M
- MRNA 11.8M
- Earning Date
- PEGA 10-21-2025
- MRNA 11-06-2025
- Dividend Yield
- PEGA 0.20%
- MRNA N/A
- EPS Growth
- PEGA 116.89
- MRNA N/A
- EPS
- PEGA 1.46
- MRNA N/A
- Revenue
- PEGA $1,732,325,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- PEGA $18.29
- MRNA N/A
- Revenue Next Year
- PEGA $6.66
- MRNA $10.38
- P/E Ratio
- PEGA $40.40
- MRNA N/A
- Revenue Growth
- PEGA 17.00
- MRNA N/A
- 52 Week Low
- PEGA $29.84
- MRNA $23.04
- 52 Week High
- PEGA $68.10
- MRNA $48.92
- Technical
- Relative Strength Index (RSI)
- PEGA 49.43
- MRNA 45.46
- Support Level
- PEGA $57.23
- MRNA $23.04
- Resistance Level
- PEGA $63.97
- MRNA $25.56
- Average True Range (ATR)
- PEGA 2.35
- MRNA 1.52
- MACD
- PEGA -0.52
- MRNA -0.25
- Stochastic Oscillator
- PEGA 24.75
- MRNA 28.15
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.